Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Pfizer recorded lower first-quarter revenue on a 75% drop in sales of its Covid-19 treatment, which more than offset growth ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential tariff effects.

The company disclosed revenue of $13.7 billion and adjusted earnings of $0.92 per share, compared to consensus estimates of ...

Pfizer said today it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Few would dispute that Pfizer (NYSE: PFE) is an icon within the pharmaceutical world. And, giving credit where it's due, the ...